SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ozarus is an AI-powered on-chain intelligence platform built on Solana, designed to protect traders and communities from scams, rugpulls, and high-risk tokens. The platform scans thousands of tokens daily, providing real-time risk scores, security audits, and token reliability insights. Its mission is to make Solana’s ecosystem safer, transforming trading from speculation-driven chaos into a transparent, data-backed environment.

Ozarus

Ozarus Crypto is trending as community members discuss potential breakouts and early entry points. Conversations highlight positive sentiment and strong support levels, with many watching for increased volume. The crypto is associated with other tokens like SOL, BTC, and PEPE, and is referred to as a potential "moonshot."

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

Fueled by community-driven momentum, $SLAP is trending as a viral social token born from meme hype. Community members express bullish sentiment and highlight its unique energy, pointing to real-life partnerships, sponsored athletes like Karolina Arm, and a dedicated team.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as the community debates its future, particularly its ability to attract users and projects compared to other blockchains. Discussions include the performance of its CEO and speculation about potential ETF developments, with some suggesting the need for a new direction. Bullish sentiment persists among some, who cite Google partnerships and quantum-resistant technology as reasons for optimism.

Fiverr International Ltd. develops an e-commerce platform that allows people to buy and sell digital services. It operates through the following geographical segments: U.S., Europe, Asia Pacific, Rest of the World and Israel. The firm offers digital marketing, graphics and design, video and animation, writing and translation, and music and audio. The company was founded by Micha Kaufman and Shai Wininger in 2009 and is headquartered in Tel Aviv, Israel.

Fiverr International Ltd

Fiverr ($FVRR) is trending as the community discusses its potential turnaround, focusing on a double bottom technical pattern and upcoming earnings. Some investors believe that the company, despite recent challenges, is undervalued and poised for growth as rate cuts occur. Others express concerns about AI's impact on the gig economy and the company's connection to Israel.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid community discussions about potential price movements and comparisons to other meme coins like Dogecoin and Bonk. Some users are expressing frustration with its performance, while others remain optimistic, awaiting potential catalysts or a broader altcoin season. There are also conversations around market capitalization and supply.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience. The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency <1 second. The chain currently supports 100k orders / second. The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1. The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

Hype Crypto ($HYPE) is trending due to its strong showing as a decentralized exchange (DEX) and Layer-1 ecosystem, prompting discussions about its potential to rival established platforms like Binance and even surpass Solana ($SOL). Community members are actively encouraging others to add HYPE to their watchlists, emphasizing its innovative features, liquidity, and status as a 'finance demon' that everyone should know about.  The recent launch of an AI trading bot and news surrounding quantum-resistant infrastructure are also driving interest.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

VIR is trending due to institutional investment updates and upcoming presentations regarding its Hepatitis Delta clinical results. Community discussions revolve around Softbank's share disposals and potential market manipulation, alongside long-term prospects related to HIV antibody development and cancer therapies. Recent analyst ratings and the initiation of Phase 3 trials are also contributing to the stock's visibility.

The Real FartCoin as suggested by Truth Terminal, following the "FartCoin Launch Strategy". Full FartCoin Ecosystem with a major focus on Planting Trees across the world.  FartNFTs,FartDAO,FartSwap and many other applications are part of our movement. With the also correct Token Mechanics such as the correct Ticker, Supply, Blockchain and Purpose of the token.  Community ran and funded, with great intentions to follow up with the full "lore" of the FartCoin!

FartCoin

FartCoin is trending as traders discuss its potential amid the current meme coin frenzy, with some pointing to its low market cap and potential for significant gains. Community members are comparing it to other popular meme coins, speculating whether it will be the next big mover in the crypto space. The coin is also being discussed in relation to other trending cryptos, with some users suggesting it could ignite an 'alt season'.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending as retail investors discuss the potential for a short squeeze, citing a perfect setup and recent volume increases. Community members are also speculating about a potential buyout offer, while expressing frustration over perceived stock price suppression despite positive Q3 revenue and synergies from the Melinta deal. The community is actively debating the influence of Deerfield's convertible notes and advocating for increased communication from CorMedix's management.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid discussions around tariffs and trade relations, particularly with Canada, following a recent ad dispute and tariff imposition. The community is engaged in heated debates regarding the implications of these policies and the broader political landscape. Some users are focused on the stock's performance, while others are discussing political and economic issues.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.</li><li>The Data Monitoring Committee found no convincing evidence that the serious adverse event is related to ARCT-032 and approved the study to proceed. &nbsp;</li></ul>Arcturus Therapeutics Holdings (ARCT) on Wednesday announced interim results from a mid-stage trial of its ARCT-032 therapy in people with cystic fibrosis.In a cohort of the study, six patients with cystic fibrosis received inhaled 10 mg doses of ARCT-032 daily over 28 days.<h2 class="st-heading-2">What’s Driving Down The Stock?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-provides-interim-phase-2-data-cystic">reported</a> that treatment-related adverse events were observed in the study during the initial doses but ceased with continuous dosing.However, the Data Monitoring Committee found no convincing evidence that the serious adverse event is related to ARCT-032 and approved the study to proceed, the company said. One treatment-related adverse event also occurred in a participant after the end of the dosing period, it said. Furthermore, the treatment was generally safe and well-tolerated, the company added.However, shares of the company fell 58% on Wednesday. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARCT">ARCT stock</a> rose from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<h2 class="st-heading-2">What Are The Firm’s Plans Ahead?</h2>Arcturus noted on Wednesday that an expanded third cohort is ongoing. The company aims to enroll up to six subjects in the cohort if there is a dose escalation response at 15 mg and if ARCT-032 continues to be generally safe and well-tolerated.The company also said that it intends to kickstart a 12-week safety and preliminary efficacy study in up to 20 cystic fibrosis participants in the first half of 2026.Cystic fibrosis (CF) is an inherited genetic disorder that causes thick, sticky mucus to build up in the body's organs, primarily affecting the lungs and pancreas. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.<blockquote>“We are particularly encouraged by the early signals of mucus plug reduction in Class I CF participants treated with ARCT-032 because Class I CF individuals do not produce CFTR and therefore do not respond to available CFTR modulator therapy.”— Juergen Froehlich, Chief Medical Officer, Arcturus</blockquote>ARCT stock is down 43% this year and 51% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-to-recall-nearly-13000-vehicles-in-us/cLG57HOR3q4">Tesla To Recall Nearly 13,000 Vehicles In US, But Retail Has Its Eyes Set On Q3 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medical syringe is seen with Arcturus Therapeutics company logo displayed on a screen in the background in this illustration photo taken in Poland on June 16, 2020. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Arcturus Therapeutics Stock Plunges Over 58% Today: What’s Causing The Sell-Off?

The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.

Equity

Zacks.com featured highlights include Flux Power, Aura Minerals, Arcturus Therapeutics and Sterling Infrastructure

Flux Power, Aura Minerals, Arcturus Therapeutics, and Sterling Infrastructure show strong price momentum amid market uncertainty.

Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?

Arcturus Therapeutics (ARCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4 Stocks With Recent Price Strength to Maximize Your Gains

FLUX, AUGO, ARCT and STRL are showing notable price strength amid a volatile market.

Are Medical Stocks Lagging  Aquestive Therapeutics (AQST) This Year?

Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.

Arcturus Therapeutics (ARCT) is on the Move, Here's Why the Trend Could be Sustainable 

Arcturus Therapeutics (ARCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +69.37% and +20.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.90	--	--	N/A
Q2 '25	-$0.89	-$0.34	61.87%	BEAT
Q1 '25	-$1.18	-$0.52	55.85%	BEAT
Q4 '24	-$0.55	-$1.11	-102.39%	MISSED
Q3 '24	-$1.22	-$0.26	78.62%	BEAT

ARCT
Arcturus Therapeutics Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ARCT News

ARCTArcturus Therapeutics Holdings Inc